Takafumi Tanei

Dr. Takafumi Tanei

Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in World Neurosurgery
Verified
Journal Article
Closed access
THToshinori Hasegawa
Toshinori Hasegawa
TKTakenori Kato
Takenori Kato
TNTakehiro Naito
Takehiro Naito
Takafumi TaneiTakafumi Tanei
Takafumi Tanei
JTJun Torii
Jun Torii
Taku SugiyamaTaku Sugiyama
Taku Sugiyama

21 April 2009 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
Takafumi TaneiTakafumi Tanei
Takafumi Tanei
YKYasukazu Kajita
Yasukazu Kajita
YKYoshiki Kaneoke
Yoshiki Kaneoke
STShigenori Takebayashi
Shigenori Takebayashi
DNDaisuke Nakatsubo
Daisuke Nakatsubo
TWToshihiko Wakabayashi
Toshihiko Wakabayashi

1 January 2019 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
Takafumi TaneiTakafumi Tanei
Takafumi Tanei
YKYasukazu Kajita
Yasukazu Kajita
STShigenori Takebayashi
Shigenori Takebayashi
KAKosuke Aoki
Kosuke Aoki
NNNorimoto Nakahara
Norimoto Nakahara
TWToshihiko Wakabayashi
Toshihiko Wakabayashi
The efficacy and predictive factors associated with successful spinal cord stimulation (SCS) for central post-stroke pain (CPSP) have yet to be definitively established. Thus, this study evaluated the rates of pain relief found after more than 12 months and the predictive factors associated with the success of SCS for CPSP. The degree of pain after SCS in 18 patients with CPSP was assessed using the Visual Analog Scale preoperatively, at 1, 6 and 12 months after surgery, and at the time of the last follow-up. After calculating the percentage of pain relief (PPR), patients were separated into two groups. The first group exhibited continuing PPR ≥30% at more than 12 months (effect group) while the second group exhibited successful/unsuccessful trials followed by decreasing PPR <30% within 12 months (no effect group). Pain relief for more than 12 months was achieved in eight out of 18 (44.4%) patients during the 67.3 ± 35.5 month follow-up period. Statistically significant differences were found for both the age and stroke location during comparisons of the preoperative characteristics between the two groups. There was a significantly younger mean age for the effect versus the no effect group. Patients with stoke in non-thalamus were significantly enriched in effect group compared with those with stoke in thalamus. Multivariable analysis using these two factors found no statistical differences, suggesting that these two factors might possibly exhibit the same behaviors for the SCS effect. These results suggest that SCS may be able to provide pain relief in young, non-thalamus stroke patients with CPSP.

1 January 2008 in Neurologia medico-chirurgica
Verified
Journal Article
Closed access
Takafumi TaneiTakafumi Tanei
Takafumi Tanei
KFKazuhiro Fukui
Kazuhiro Fukui
KWKenichi Wakabayashi
Kenichi Wakabayashi
YMYuki Mitsui
Yuki Mitsui
NINorio Inoue
Norio Inoue
MWMasao Watanabe
Masao Watanabe
Three of 4 cases of dural arteriovenous fistulas (DAVFs) in the anterior cranial fossa were detected incidentally by magnetic resonance (MR) imaging, and one case manifested as intracerebral hemorrhage. Cerebral angiography revealed fistulas located in the anterior cranial fossa. Three patients underwent surgery, and the fistulas were successfully obliterated. One patient with nonruptured DAVF requested conservative medical management. Incidental detection of asymptomatic or nonruptured DAVFs in the anterior cranial fossa has increased with the wider use of MR imaging. Increase in the size of a venous varix is the indicator for aggressive therapeutic intervention in a patient receiving conservative medical management for asymptomatic or nonruptured DAVFs in the anterior cranial fossa.

1 January 2013 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
Takafumi TaneiTakafumi Tanei
Takafumi Tanei
TNTetsuya Nagatani
Tetsuya Nagatani
NNNorimoto Nakahara
Norimoto Nakahara
TWTadashi Watanabe
Tadashi Watanabe
TNTomoki Nishihata
Tomoki Nishihata
TWToshihiko Wakabayashi
Toshihiko Wakabayashi
The usefulness of 1.5-T high-field intraoperative magnetic resonance (iMR) imaging during transsphenoidal surgery for functioning pituitary adenomas was retrospectively evaluated based on long-term endocrine remission from the records of 14 patients who underwent transsphenoidal surgery with iMR imaging for functioning pituitary microadenomas and small adenomas located in the intrasellar region. The maximum tumor diameter was 9.3 ± 2.6 mm. Patients were diagnosed with acromegaly (n = 7), prolactinoma (n = 4), and Cushing's disease (n = 3). If iMR imaging detected tumor remnants after resection, the resection cavity was reexamined and further resection was performed. Postoperative endocrine follow-up period was mean 33.7 ± 13.3 months. Tumor remnants were detected after the first resection in seven patients. Further resection was performed in five of these patients, and three achieved long-term endocrine remission. As a result, the overall long-term endocrine remission rate was 78.5% (11/14), instead of the 57.1% (8/14) that would be expected if iMR imaging had not been performed. Long-term endocrine remission had a tendency to be associated with the absence of tumor remnants on the final iMR images, but this was not significant (p = 0.09). Long-term endocrine remission was associated with presence of tumor remnants in the cavernous sinus on the final iMR images (p = 0.03). High-field iMR imaging is useful for depicting tumor remnants after resection, and increased the long-term endocrine remission rate for patients with functioning pituitary microadenomas and small adenomas.

1 January 2011 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
Takafumi TaneiTakafumi Tanei
Takafumi Tanei
YKYasukazu Kajita
Yasukazu Kajita
HNHiroshi Noda
Hiroshi Noda
STShigenori Takebayashi
Shigenori Takebayashi
DNDaisuke Nakatsubo
Daisuke Nakatsubo
TWToshihiko Wakabayashi
Toshihiko Wakabayashi
Motor cortex stimulation (MCS) has now become the preferred option for neurosurgical management of intractable central neuropathic pain such as post-stroke pain and trigeminal neuropathic pain. However, the efficacy of MCS for other central neuropathic pain such as pain resulting from spinal cord or brainstem lesions is unclear. We retrospectively reviewed 11 consecutive patients with intractable central neuropathic pain who underwent MCS in our institution. Eight patients had poststroke pain caused by thalamic hemorrhage (n = 5) or infarction (n = 3) (thalamic group). Two patients had postoperative neuropathic pain caused by spinal cord lesions, and one patient had facial pain caused by a brainstem lesion associated with multiple sclerosis (brainstem-spinal group). Visual analog scale and stimulation parameters were evaluated at 1 and 6 months postoperatively. MCS was effective for six of eight patients in the thalamic group, and all three patients in the brainstem-spinal group. These efficacies continued for 6 months after surgery without significant change in the stimulation parameters compared with the parameters at 1 month in both groups. The mean amplitude at 1 month and frequency at 6 months after surgery were significantly higher in the brainstem-spinal group than the thalamic group, although the patient number was small. MCS is effective for other central neuropathic pain, but higher intensity stimulation parameters may be necessary to gain adequate pain reduction.